Short-term kinetics of tumor antigen expression in response to vaccination

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1809-1820

  Ohnmacht, G A ^a   Wang, E ^a   Mocellin, S ^a   Abati, A ^a   Filie, A ^a   Fetsch, P ^a   Riker, A I ^a   Kammula, U S ^a   Rosenberg, S A ^a   Marincola, F M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; GLYCOPROTEIN GP 100; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; ASPIRATION BIOPSY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR REGRESSION; VACCINATION;

EID: 0035423414     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1809     Document Type: Article

References (41)

1. New paths in human cancer serology
2. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
3. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
4. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
5. Expression of gp100 in melanoma metastases resected before or after treatment with IFNα and IL-2
6. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo
7. Immune selection following antigen specific immunotherapy of melanoma
8. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
9. Molecular classification of cutaneous malignant melanoma by gene expression: Shifting from a continuous spectrum to distinct biologic entities
10. Antigens recognized by T-lymphocytes on human tumours
11. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation
12. Reduced levels of DNA 5-methylcytosine in metastatic variants of the human melanoma cell line MeWo
13. + cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
14. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions
15. HLA class I antigen down-regulation in human cancers: T-cell immunotherapy revives an old story
16. Functional dissociation between local and systemic immune response following peptide vaccination
17. Identification of a tumor-infiltrating lymphocyte recognizing MAGE-12 in a melanoma metastasis with decreased expression of melanoma differentiation antigens
18. A natural history of melanoma: Serial gene expression analysis
19. High fidelity mRNA amplification for gene profiling using cDNA microarrays
20. Real time quantitative PCR
21. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood
22. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
23. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T-lymphocytes
24. Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions
25. Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: Use in the characterization of the human melanoma antigen MART-1
26. Fine specificity and idiotype diversity of the murine anti-HLA- A2, A28 monoclonal antibodies CR11-351 and KSI
27. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
28. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma
29. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
30. Structure, chromosomal localization and expression of 12 genes of the MAGE family
31. Aspiration biopsy of metastatic carcinoma in lymph nodes of the neck: A review of 1101 consecutive cases
32. Fine-needle aspiration effects on benign lymph node histology
33. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12
34. Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases
35. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
36. + T cells
37. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immiunodominant epitope
38. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
39. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
40. Heteroduplex analysis in bemophilia B: Detection of two novel factor IX gene mutations
41. Is cancer dangerous to the immune system?